Retina Implant has secured CE mark approval for its Alpha AMS device to sell in the European economic area.
The next generation Alpha AMS device has been developed to restore some useful vision in patients blinded by the degenerative eye condition.
Alpha IMS is the wireless subretinal implant technology that first received CE mark approval in 2013.
Since 2014, the next-generation device is being tested in clinical trials across Germany and the UK.
The company said the technology has an increased number of pixels with 1600 and is estimated to last several years in the body.
Retina Implant CEO Walter-G Wrobel said: "We are delighted by the news that our latest device has received the CE mark.
"We believe that being able to provide physicians access to the Alpha AMS represents a notable step forward in treatment options for their patients.
"We would also like to thank those patients who participated in the clinical trials to date – they have been critical to the success of our research and evolution of the Alpha AMS."
Retina Implant produces subretinal implants to treat patients blinded by retinitis pigmentosa (RP).